Solvonis Therapeutics plc
SVNS.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | -£0 | -£0 | £0 | £0 |
| Revenue | – | £0 | £0 | £0 |
| % Growth | – | – | -100% | – |
| Gross Profit | – | £0 | -£0 | £0 |
| % Margin | – | – | – | 8.6% |
| EBITDA | – | -£0 | -£0 | -£0 |
| % Margin | – | – | – | -553% |
| Net Income | – | -£0 | -£0 | -£0 |
| % Margin | – | – | – | -574.6% |
| EPS Diluted | – | -0.003 | -0.005 | -0.019 |
| % Growth | – | 46% | 74% | – |
| Operating Cash Flow | – | -£0 | -£0 | -£0 |
| Capital Expenditures | – | £0 | -£0 | £0 |
| Free Cash Flow | – | -£0 | -£0 | -£0 |